Oura will struggle to justify its pulse-racing valuation of $16bn

By the Editorial Team · Thursday, September 17, 2026

Finnish-American wearable tech company Oura is preparing for an IPO that could value it at approximately $16 billion, reflecting strong investor interest in its smart ring products that track health metrics. The offering highlights both the growing market for preventive healthcare devices and the challenges Oura faces in achieving long-term profitability and greater clinical acceptance.

Finnish-American wearables company Oura is preparing for an initial public offering (IPO) that could value the business at around $16 billion, underscoring growing investor interest in preventive healthcare technologies. Known for its smart rings that track sleep and activity metrics, Oura is joining a broader market trend in wearable devices, which industry analysts estimate could generate up to $1 trillion in sales globally between 2023 and 2032. Within this market, smart rings represent a $44 billion segment, significantly smaller than the $300 billion-plus market for smartwatches and hearing devices.

Oura’s rings, endorsed by public figures such as Kim Kardashian and Gwyneth Paltrow, have found a dedicated user base partly attracted by data-driven health insights. The company, founded 13 years ago, occupies a space between lifestyle gadgets and medical devices, though it has not sought direct regulatory approval for its health-related functions. Last year, Oura appointed its first chief medical officer and has partnered with Essence Healthcare to provide certain insurance plan members with access to Oura rings coupled with medical data monitoring by healthcare professionals.

Continuous health monitoring, such as Oura’s, holds potential for earlier detection of medical conditions compared to traditional periodic doctor visits. Major technology companies including Apple, Samsung, and Google’s Fitbit have secured regulatory clearances for features detecting conditions like arrhythmia, sleep apnea, and hypertension, strengthening the case for such devices in preventive care.

Despite these developments, the proposed valuation of $16 billion raises questions among market observers. Industry benchmarks show that established device manufacturers like Apple and Garmin typically trade around 20 times their forward earnings before interest, taxes, depreciation, and amortization (EBITDA). In contrast, Oura’s valuation implies a multiple of about 80 times forward EBITDA, even assuming a doubling of EBITDA this year. Achieving valuation parity with these larger peers would require sustained profit growth over several years.

The broader adoption of health wearables also faces challenges linked to professional acceptance. A recent survey by the American Medical Association indicated that while 80% of surveyed physicians personally use wearables, many expressed concerns related to legal liability and the potential burden of monitoring patient-generated health data. Overcoming these issues is considered crucial for companies like Oura to move beyond lifestyle appeal and gain deeper integration into clinical practice.

Nevertheless, Oura’s organic growth through word-of-mouth referrals suggests a strong consumer enthusiasm for the product. About 40% of the company’s new users reportedly come from recommendations, indicating a committed user base that could support its expansion amid ongoing debates over valuation and clinical validation.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.